Document:

Summary of Key Terms of Employment Arrangement

 Exhibit 10.28 
 [PATHEON] 
  

					
		 		 	 Wesley P. Wheeler

Chief Executive Officer & President
 Patheon Inc
 PO Box 110145
 Research Triangle Park, NC 27709
 Phone: 919-226-3201

Fax: 919-226-3202

wes.wheeler@patheon.com

March 17, 2010 
 PRIVATE AND
CONFIDENTIAL 
 RE: Terms of Employment 
 Mark J. Kontny, Phd. 
 573 Shoreline Drive 
 Grayslake, IL 60030 
 Dear Mark: 
 Further to our discussions, I am pleased to present these revised terms of employment to you as President, Global Pharmaceutical Development Services and Chief Scientific Officer (President, Global
PDS & CSO), with Patheon Pharmaceutical Services Inc. (“Patheon”), commencing April 15, 2010. Attached hereto, as Exhibit A, is a summary of the key terms of your employment arrangement Your employment with Patheon shall be
governed by the terms set forth on Exhibit A, subject to the execution of an employment agreement between you and Patheon on substantially the terms set forth on Exhibit A (the “Employment Agreement). 

By executing this letter, you agree that your employment will be governed by the terms set forth on Exhibit A, subject to the final execution of the
Employment Agreement. 
 Mark, I am truly looking forward to working with you. 

 

	
	Very truly yours,
	
	/s/ Wesley P. Wheeler
	
	Wesley P. Wheeler
	Chief Executive Officer
	
	Accepted as of this 19th Day of March, 2010
	
	 /s/ Mark J. Kontny

	Mark J. Kontny, PhD

 EXHIBIT A 
 Summary of Key Terms 
 For Proposed Employment between Patheon
Pharmaceutical Services, Inc. 
 (the “Company”) 

and 

Mark J. Kontny (“Executive”) 
  

	1.	Title 

 President, Global
Pharmaceutical Development Services & Chief Scientific Officer (“President, Global PDS & CSO”). 

Position reports to the Chief Executive Officer and President (“CEO & President”). 

 

	2.	Term and Effective Date 

Indefinite term with start date of April 15, 2010 (“Effective Date”) 

 

	3.	Location of Duties 

 The
Executive’s principal office will be at the US Headquarters location in Durham, North Carolina. The Executive will be required to relocate to the Raleigh/Durham area as a condition of employment. The Executive will be eligible for relocation
assistance in accordance with the North American Tier 1 program. The Executive’s move must be completed within 9 months. 
  

	4.	Direct Reports and Functional Responsibility 

 The Executive will serve as the President, Global Pharmaceutical Development Services & Chief Scientific Office (CSO); with such authority, duties and responsibilities as are commensurate with
such position, reporting to the Chief Executive Officer & President. In addition the Executive will be a member of the Patheon Executive Committee and become legal officer on all related subsidiaries as needed. 

The Executive will have the responsibility for leading the Company’s strategy for global PDS initiatives and providing strong R&D
stewardship for the Company, including full P&L leadership responsibilities. 
  

	5.	Base Salary 

 $400,000 USD
annually. 

	6.	Performance Bonus 

Executive will be eligible to receive a target performance bonus of 45% of Executive’s Base Salary, based on achieving predetermined
financial and other targets set by the Chief Executive Officer and President. 
  

	7.	Equity Compensation – Stock Options 

 Executive will he eligible to participate in the Company’s Stock Option Plan and awarded options from time to time in accordance with the terms of such plan. 

Any options granted shall vest as to one-third per year over the first three years of the grant. All options granted to the Executive will
expire seven (7) years from the grant date. 
  

	8.	Initial Grant of Stock Options 

 As an initial grant to the Executive, subject to approval of the Board of Directors at a meeting following the Effective Date of this agreement, the Executive would receive a stock option grant of 350,000
options under the terms of the Patheon Stock Option Plan. As per securities regulatory requirements, options may not be issued when the Company is in possession of material undisclosed information. The options shall vest as to one-third per year
over the first three years. The subscription price for the shares under option will be the market price (as defined in the Patheon Stock Option Plan) on the day the grant is approved by the Committee. 

In addition to the initial grant, Executive will be entitled to participate as a senior executive of the Company, in the opportunity to be
granted further options at the discretion of the Board of Directors in the course of their periodic review of executive compensation arrangements. 
 Executive will be expected to comply with the terms of any share ownership program implemented by the Company. 
  

	9.	Employee Benefits 

Executive will be entitled to participate in the employee welfare benefit programs of the Company on a basis at least as favorable as
other senior-level executives of the Company including medical, dental, life insurance, 401-K retirement plans and other health benefit programs. 
 In addition, the Executive will be entitled to four (4) weeks of vacation time. 
  

	10.	Perquisites 

 Executive
will be entitled to an allowance of $1,200 USD per month for car related expenses subject to the normal statutory and withholding deductions. 

	11.	Sign-On Cash Compensation 

The Company will pay Executive within 30 business days of the Effective Date, a sign-on bonus of US $ 75,000. 

 

	12.	Severance 

 In the event
the Executive’s employment is terminated by the Company without Cause or if the Executive terminates employment with the Company for Good Reason (as defined below), the Executive will be entitled to receive an amount equal to (i) 12 months
Base Salary and (ii) an additional amount, determined by the Board of Directors in its sole discretion, equal to the bonus he would reasonably be expected to have earned during the fiscal year in which his employment is terminated. The
Executive shall be entitled to this severance benefit only if he executes and does not revoke a Company-drafted waiver and release within a prescribed time period following termination of employment. 

The severance benefit described above shall generally be paid in equal installments over 12 months, beginning after the date the waiver
and release becomes irrevocable. However, to the extent that the Executive’s severance payment exceeds two times the lesser of (i) the Executive’s annual compensation or (ii) the IRS compensation limit for the year of
termination, any amounts not yet paid as of the “short-term deferral date” shall be paid in a lump sum on the “short-term deferral date.” The “short-term deferral date” is the date that is two and one-half months after
the end of the later of (i) the calendar year in which the Executive’s employment is terminated or (ii) the Company’s fiscal year in which the Executive’s employment is terminated. 

“Good Reason” means the occurrence of any of the following events without the consent of the Executive: (i) a
material reduction by the Company of the Executive’s duties or responsibilities or the assignment to the Executive of duties or responsibilities or the assignment to the Executive of duties materially inconsistent with such position;
(ii) a material breach by the Company of this Agreement; or (iii) requirement by the Company that the Executive’s work more than fifty (50) miles from Executive’s principle office upon commencement of Employment. A
termination of the Executive’s employment by Executive shall not be deemed to be for Good Reason unless (i) the Executive gives notice to the Company of the existence of the event or condition constituting Good Reason within 30 days after
such event or condition initially occurs or exists, (ii) the Company fails to cure such event or condition within 30 days after receiving such notice, and (iii) the Executive’s “separation from service” within the meaning of
Section 409A of the Code occurs not later than 90 days after such event or condition initially occurs or exists. 
 In the
event of termination for Cause, the Executive shall not be entitled to severance. 
 For purposes of this agreement
“Cause” means the determination, in good faith, by the Board, after notice to the Executive and, if curable, a reasonable opportunity to cure, that one or more of the following events has occurred: (i) Executive has failed to
perform his material duties, and such failure has not been cured after a period of 30 

 
days notice from the Company; (ii) any reckless or grossly negligent act by Executive having the effect of injuring the interest, business or reputation of the Company, or any of its parent,
subsidiaries or affiliates in any material respect; (iii) Executive’s commission of any felony (including entry of a nolo contendere plea); (iv) any misappropriation or embezzlement of the property of the Company, or any
of its parent, subsidiaries or affiliates; or (v) a breach of any material provision of the Employment Agreement by Executive. 
  

	13.	Change in Control 

Notwithstanding the foregoing, in the event that the Executive’s employment is terminated by the Company without Cause or terminated
by the Executive for Good Reason at any time during the 6 month period following the consummation of a Change in Control (as defined below), the Executive will be entitled to receive (i) 12 months Base Salary and (ii) an additional amount,
determined by the Board of Directors in its sole discretion, equal to the bonus he would reasonably be expected to have earned during the fiscal year in which his employment is terminated. The Executive shall be entitled to this benefit only if he
executes and does not revoke a Company-drafted waiver and release within a prescribed time period following termination of employment. 
 The severance benefit described above shall generally be paid in equal installments over 12 months, beginning after the date the waiver and release becomes irrevocable. However, to the extent that the
Executive’s severance payment exceeds two times the lesser of (i) the Executive’s annual compensation or (ii) the IRS compensation limit for the year of termination, any amounts not yet paid as of the “short-term deferral
date” shall be paid in a lump sum on the “short-term deferral date.” The “short-term deferral date” is the date that is two and one-half months after the end of the later of (i) the calendar year in which the
Executive’s employment is terminated or (ii) the Company’s fiscal year in which the Executive’s employment is terminated. 
 In addition, in the event that the Executive’s employment is terminated by the Company without Cause or terminated by the Executive for Good Reason at any time during the 6 month period following the
consummation of a Change in Control the Executive’s unvested options will be considered vested and exercisable and remain in force for the duration of the original term. 
 “Change in Control” means any of the following events: 
 Any
“Person” (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than JLL Partners or its affiliates, becomes a Beneficial Owner (within the
meaning of Exchange Act Rule 13d-3) of more than fifty percent (50%) of the voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors: 

There is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other Company,
other than a merger or 

 
consolidation that would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or
by being converted into voting securities of the surviving entity or any parent thereof) at least fifty percent (50%) of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding
immediately after such merger or consolidation; or 
 The stockholders or the Company approve a plan of complete liquidation or
dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 
  

	14.	Other 

 Confidentiality,
one year non-solicit/no-hire and one year non-competition covenants. 
 The Executive to represent that he is under no employment
contract, non-competition or other covenants or restrictions that could limit his ability to commerce work on the Effective Date or otherwise limits his ability to perform all responsibilities of the position. 

 

	15.	Governing Law 

 North
Carolina 
  

	16.	Section 409A Compliance 

 The compensation and benefits described in this summary are designed to be exempt from, or to comply with, Section 409A of the Internal Revenue Code (“Section 409A”). The terms of
employment described in this summary will be reflected in an employment agreement, which shall include all necessary provisions to ensure exemption from or compliance with Section 409A. The Executive shall have the opportunity to have the
agreement reviewed by counsel prior to signature. In order to comply with Section 409A, the agreement must be finalized by the end of the calendar year that includes the Effective Date.Offer Letter from Patheon to Doaa A. Fathallah dated February 20, 2008

 [PATHEON] 
 Exhibit 10.29 
 February 20, 2008 

PRIVATE AND CONFIDENTIAL 
 Doaa A.
Fathallah 
 Weidstrasse 11, 6300 
 Zug,
Switzerland, 
 RE: Terms of Employments  
 Dear Doaa: 
 I am pleased to present these terms of employment for you as General Counsel, Europe
and Global Pharmaceutical Development Services (“PDS”) with Patheon Inc. (“Patheon”), commencing March 3, 2008. Attached hereto as Revised Exhibit A-1 is a summary of the key terms of your employment arrangements.
Patheon agrees that your employment by Patheon will be governed by the terms set forth on Revised Exhibit A-1, subject to the execution of an employment agreement between you and Patheon on substantially the terms set forth on Revised
Exhibit A-1 (the “Employment Agreement”). 
 By executing this letter, you agree that your employment will be governed by the
terms set forth on Revised Exhibit A-1 , subject to the final execution of the Employment Agreement 
 Doaa, I am looking forward to
working with you once again 
  

			
	Very truly yours, PATHEON INC.
		
	By:	 	/s/ Wesley P. Wheeler
		 	Wesley P. Wheeler
		 	Chief Executive Officer

 Accepted as of this
             Day of 
 February, 2008 

 

	
	
	/s/ Doaa A. Fathallah
	Doaa A. Fathallah

 [PATHEON] 
 Revised EXHIBIT A-1 
 Summary of Key Terms 

For Proposed Employment between Patheon Inc (the “Company”) 

and 

Doaa A. Fathallah (“Executive”) 
  

	1.	Title and Position 

Executive’s title shall be Senior Vice President, General Counsel, Europe and Global Pharmaceutical Development Services
(“PDS”). Executive’s title shall be adjusted pursuant to Patheon’s expansion into Asia. The Position reports directly to Chief Executive Officer (“CEO”) with dotted line reporting to President – Europe and
President – PDS. Executive and the General Counsel, North America and Corporate Secretary shall coordinate to address Company administrative matters as necessary. 
 Executive shall become a member of the European Executive Management team. Executive shall become legal officer for (i) all existing European businesses, affiliates and subsidiaries and (ii) any
newly acquired businesses, affiliates and subsidiaries pursuant to Patheon’s expansion in Asia 
 Executive will be employed
by the US Patheon Pharmaceutical Services Inc. organization. 
  

	2.	Term and Effective Date 

Indefinite term with start date to be agreed upon between Executive and CEO (“Effective Date”). 

 

	3.	Location of Duties 

 It is
understood that the Executive’s principal office will be a home office located in the Executive’s residence in the city of Zug, Switzerland. Patheon shall cover all reasonable costs associated with setting up and maintaining
Executive’s home office, including but not limited to acquiring the necessary office equipment, supplies and set up services, and maintaining all necessary services, as consistent with applicable Patheon policy and procurement practices. Such
amount to be in accordance with policy and require the normal and customary approvals. 

 Further and dependent upon the needs of the organization, Executive and Patheon Inc may
enter into discussions as to a potential repatriation back to the US to serve in a global corporate office capacity. This global corporate office location has yet to be determined. 

 

	4.	Direct Reports and Functional Responsibility 

 The Executive shall have responsibility for all legal matters for Europe, Global PDS and any expansion into Asia 
 As of the Effective Date, the Executive shall have 2 direct reports as follows: 

Head Legal Counsel in Italy 
 Head Legal Counsel in the UK 
 Executive shall have the discretion to determine and
meet future personnel needs of the legal department relating to Europe, Global PDS and any expansion into Asia, subject to the normal and customary headcount approval processes. 

 

	5.	Base Salary 

$300,000 US annually (“Base Salary”). This annual base salary is commensurate with expatriation duties and responsibilities
while abroad in Europe. Dependent upon both the Executives repatriation back to the US, and the nature of those repatriated duties, this compensation may be adjusted to reflect the new responsibilities. 

For fiscal 2008, Base Salary will be prorated from Effective Date. 

 

	6.	Performance Bonus 

Executive shall be eligible to receive a target performance bonus of 40% of Executive’s Base Salary, based on achieving predetermined
financial and other targets set by the CEO in consultation with Executive. Should Executive exceed target performance, Executive shall receive, dependent upon the above plan level up to a maximum bonus of 60 % of Executive’s Base Salary.

 For fiscal 2008, Performance Bonus will be prorated from the Effective Date. 

 

	7.	Sign-On Bonus 

 Executive
shall be paid a sign-on bonus in the amount of $50,000 US within 30 days of Effective Date. Executive shall reimburse Patheon this amount should Executive resign for other than Good Reason within (as defined herein) one year of the Effective Date.

	8.	Equity Compensation — Stock Options 

 Executive will be eligible to participate in the Corporations Stock Option Plan and awarded options from time to time in accordance with the terms of such plan. 

Any options granted shall vest as to one-third per year over the first three years of the grant. All options granted to the Executive will
expire seven (7) years from the grant date. 
  

	9.	Initial Grant of Stock Options 

 As an initial grant to the Executive, subject to Board of Director approval, the Executive would receive a stock option grant of 50,000 options under the terms of the Patheon Stock Option Plan. The
options shall vest as to one-third per year over the first three years from the date you commence employment. The subscription price for the shares under option will be the market price (as defined in the Patheon Stock Option Plan) on the day your
grant is approved by the Board of Directors. 
 In addition to the initial grant, Executive will be entitled to participate as a
senior executive of the Company, in the opportunity to be granted further options at the discretion of the Board of Directors in the course of their periodic review of executive compensation arrangements. 

Executive will be expected to comply with the terms of any share ownership program implemented by the Company. 

 

	10.	Employee Benefits 

Executive will be entitled to participate in the Ambassador employee welfare benefit programs of the Company including medical, dental,
life insurance. In addition, the Executive will be eligible to participate in the US 401-K retirement plans and other health benefit programs afforded to Executives at the same level within the organization. 

In addition to the 401-K plan, Patheon is in the process of reviewing its executive compensation arrangements, including whether to
implement a Supplemental Executive Retirement Plan (“SERP”). If Patheon implements a SERP or other retirement plan available to senior executives, the Executive will be entitled to participate in that plan on terms substantially similar to
the terms applicable to other senior executives of Patheon. 
 In addition, the Executive will be entitled to twenty-five
(25) working days of vacation time per year with additional vacation time based on seniority per Patheon vacation policy. 

	11.	Perquisites 

 Executive
will be entitled to an allowance of $2,500 US per month for car related expenses subject to the normal payroll source deductions. 
 Executive shall be entitled to be reimbursed for annual roundtrip business class tickets for her and her family to travel from Europe to the United States. 

 

	12.	Severance 

 In the event
the Executive’s employment is terminated by the Company without Cause or if Executive terminates employment with Company for Good Reason (as defined below), the Executive will be entitled to receive one year Base Salary. The Executive is also
entitled to receive an amount equal to the bonus she would reasonably be expected to have earned during the year following termination. 
 “Good Reason” means the occurrence of any of following events without the prior consent of Executive: (i) removal of Executive from Executive’s position,
(ii) material reduction by the Company of Executive’s duties or responsibilities or the assignment to Executive of duties materially inconsistent with such position, (iii) requirement by the Company that Executive work more than
thirty miles from Executive’s principle office upon commencement of Employment, or (iv) material breach by the Company of Employment Agreement or Company policy, which breach remains uncured for period of 30 days after receipt by the
Company of written notice from Executive. 
 In the event of termination for Cause, the Executive shall not be entitled to
severance. 
 For purposes of this agreement “Cause” means the determination, in good faith, by the Board, after
notice to the Executive and, if curable, a reasonable opportunity to cure, that one or more of the following events has occurred: (i) Executive has failed to perform her material duties, and such failure has not been cured after a period of 30
days notice from the Company; (ii) any reckless or grossly negligent act by Executive having the effect of injuring the interest, business or reputation of the Company, or any of its parent, subsidiaries or affiliates in any material respect;
(iii) Executive’s commission of any felony (including entry of a nolo contendere plea); (iv) any misappropriation or embezzlement of the property of the Company, or any of its parent, subsidiaries or affiliates; or (v) a
breach of any material provision of the Employment Agreement by Executive. 

	13.	Change in Control 

Notwithstanding the foregoing, in the event that Executive’s employment is terminated by the Company without Cause or terminated by
Executive for Good Reason, at any time during the six-month period following the consummation of a Change in Control (as defined below), Executive will be entitled to continue to receive Base Salary payable in equal monthly installments, plus
Executive’s target performance bonus for 12 months following termination. In addition, upon the occurrence of a Change in Control, Executive’s unvested options will become immediately vested and exercisable and remain in force for the
duration of their original term. 
 “Change in Control” means any of the following events: 

Any “Person” (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)), other than JLL Partners or its affiliates, becomes a Beneficial Owner (within the meaning of Exchange Act Rule 13d-3) of more than fifty percent (50%) of the voting power of the then outstanding voting
securities of the Company entitled to vote generally in the election of directors; 
 There is consummated a merger or
consolidation of the Company or any direct or indirect subsidiary of the Company with any other Company, other than a merger or consolidation that would result in the voting securities of the Company outstanding immediately prior to such merger or
consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least fifty percent (50%) of the combined voting power of the securities of
the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation; or 
 The
stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets 

 

	14.	Other 

 Confidentiality,
one year non-solicit/no-hire. 
 Executive to represent that she is under no employment contract, non- competition or other
covenants or restrictions that could limit her ability to commence work on the Effective Date or otherwise limit her ability to perform all responsibilities of the position. 

 

	15.	Governing Law 

 New
York

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]